Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellectis has entered into a licensing agreement with the University of Minnesota, under which it has gained an exclusive right for using inventions related to TAL effector-mediated DNA recognition and cleavage.
Subscribe to our email newsletter
Under the licensing agreement, Cellectis can use all technology of the university related to any field.
The technology has shown positive results in genome engineering and is complementary to Cellectis’ proprietary meganuclease technology.
Cellectis CEO Andre Choulika said the company is making further progress in implementing its external growth policy by investing the capital raised in 2009 in the most promising technology, products and human resources that add value to, and are aligned with, our core business.
"Our teams are already leveraging this new technology and the first research reagents based on it are expected to come onto the market within twelve months," Choulika said.